top of page
  • Writer's pictureDLRG

SwiftScale featured in WIRED article on COVID-19

Updated: Feb 7, 2021

Startup aims to rapidly mass manufacture antibodies that could be deployed to treat Covid-19 patients

A biomanufacturing company spun out of the DLRG is seeking to rapidly translate an antibody therapy against COVID-19 by using cell-free biotechnology based on glycoengineered bacteria. And it could scale up the production 10 times faster than conventional methods. The company, SwiftScale Biologics, was co-founded by Matt DeLisa, the William L. Lewis Professor of Engineering in the Robert F. Smith School of Chemical and Biomolecular Engineering, and his longtime collaborator, Michael Jewett, a professor of chemical and biological engineering at Northwestern University.

To read the story, go here:

47 views0 comments

Recent Posts

See All


Commenting has been turned off.
bottom of page